The bill amends section 60A-2-204 of the Code of West Virginia to include crystalline polymorph psilocybin as a Schedule I drug, reflecting its recent approval by the FDA and DEA. This addition acknowledges the therapeutic potential of psilocybin and aligns state law with federal regulations. The existing framework for categorizing Schedule I drugs remains unchanged, ensuring that the classifications of various opiates, hallucinogenic substances, and synthetic cannabinoids are preserved while expanding the list to include newly recognized substances.

Furthermore, the bill aims to broaden the classification of controlled substances by incorporating various synthetic cannabinoids, tryptamines, depressants, and stimulants not currently listed under federal schedules II, III, IV, and V. It specifies a range of chemical compounds, including methamphetamine and benzodiazepines, and addresses the nomenclature for immediate precursors or derivatives. Additionally, the bill allows for the legal prescription, distribution, and marketing of organic psilocybin substances, specifically COMP360, contingent upon FDA approval and DEA scheduling, signaling a shift towards recognizing certain psychedelics for therapeutic use.

Statutes affected:
Introduced Version: 60A-2-204
Committee Substitute: 60A-2-204
Engrossed Committee Substitute: 60A-2-204